Medicine

Concomitant use of tizanidine and moderate or potent CYP1A2 inhibitors is contraindicated. Concomitant use of tizanidine with fluvoxamine, a potent CYP1A2 inhibitor in man, resulted in a 33-fold increase in the tizanidine AUC (plasma drug concentration-time curve) by fluvoxamine.

Tizanidine (brandnames Zanaflex, Sirdalud) is a drug which is used as a muscle relaxant. It is a centrally acting α-2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant. It is also prescribed for some symptoms of fibromyalgia[1]. Tizanidine may cause hypotension, so caution is advised when it is used in patients who have a history of

Tizanidine use occasionally causes drug induced liver injury. In controlled clinical studies, approximately 5% of patients treated with Zanaflex had elevations of liver function tests (ALT, AST) to greater than 3 times the upper limit of normal (or 2 times if baseline levels were elevated).[citation needed] Tizanidine use has been associated with hallucinations. Visual hallucinations and delusions have been reported in 5 of 170 patients (3%) in two North American controlled clinical studies.[citation needed] If therapy needs to be discontinued, especially in patients who have been receiving high doses for long periods, the dose should be decreased slowly to minimize the risk

The following agents are also listed as agonists by MeSH.[4] amidephrine amitraz anisodamine apraclonidine brimonidine cirazoline detomidine dexmedetomidine epinephrine ergotamine etilefrine indanidine lofexidine medetomidine mephentermine metaraminol methoxamine midodrine mivazerol naphazoline norepinephrine norfenefrine octopamine oxymetazoline phenylpropanolamine rilmenidine romifidine synephrine talipexole tizanidine

Consider a ligand receptor binding system. Ligand with a concentration L associates with a receptor of concentration or availability R to form a ligand-receptor complex with concentration RL. The binding potential is then the ratio ligand-receptor complex to free ligand at equilibrium and in the limit of L tending to 0, and is given symbol BP: This quantity, originally defined by Mintun[1], describes the capacity of a receptor to bind ligand. It is a limit (L << Ki) of the general receptor association equation: and is thus also equivalent to: These equations apply equally when measuring the total receptor density or the residual

Brandnames include: Monobenzon, Dermochinona, Leucodinine, Carmifal, Depigman, Superlite, Pigmex.

The buyer is also concerned with numerous other factors: Cosmetics Cost Ease of use Size availability

In the United States in 2006, the Juvenile Diabetes Research Foundation (JDRF) launched a multi-year initiative to help accelerate the availability of an artificial pancreas to people with diabetes.[15] The overall goal of the Artificial Pancreas Project is to accelerate the development, regulatory approval, and acceptance of continuous glucose monitoring and artificial pancreas technology in the shortest possible timeframe. The long term goal is for broad patient access and a thriving competitive market for these devices and products. JDRF's role in quickening the development and availability of the Artificial Pancreas consists of funding research in order to look over the outcomes

A development of the AICD is a portable external defibrillator that is worn like a vest.[7] The unit monitors the patient 24 hours a day and will automatically deliver a biphasic shock if needed. This device is mainly indicated in patients awaiting an implantable defibrillator. Currently only one company manufactures these and they are of limited availability.

Standard concentrates are manufactured as 50% and 80% w/w solutions, and sold under trade names such as BC50, BC80, BAC50, BAC80, etc. The 50% solution is purely aqueous, while more concentrated solutions require incorporation of rheology modifiers (alcohols, polyethylene glycols, etc.) to prevent increases in viscosity or gel formation under low temperature conditions.

Leave a Reply

Name (required)

Mail (will not be published) (required)

Website